Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTX202 in Advanced Solid Tumors
NCT05052268Phase 2Completed
- Sponsor
- Xilio Therapeutics
- Start
- Jan 2022
- Primary completion
- Mar 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of XTX202 in solid tumor, renal cell carcinoma (RCC) and melanoma (2 arms), sponsored by Xilio Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at 21 days, Incidence of Treatment-emergent Adverse Events at 24 months and 2 more. Started Jan 2022; status: completed.
02
Drugs
XTX202
03
Conditions
solid tumorrenal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT05052268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052268.